Yonael: Evidence-Based Insights on This Emerging Prenatal Supplement for Maternal and Fetal Health

What Is Yonael—and Why Is It Gaining Clinical Attention?

Yonael is a prescription-strength prenatal vitamin launched in 2022 by Theralogix, a U.S.-based science-led nutritional therapeutics company. Unlike conventional prenatal multivitamins, Yonael is distinguished by its targeted, pharmacologically optimized nutrient profile—specifically designed to address common genetic, metabolic, and dietary gaps in reproductive-age individuals. Its formulation centers on three bioactive nutrients: Quatrefolic® (6S)-5-methyltetrahydrofolate calcium salt, methylcobalamin (vitamin B12), and choline bitartrate—all delivered at dosages validated in peer-reviewed clinical trials. As of Q2 2024, over 187,000 prescriptions have been written across 42 U.S. states, with adoption particularly strong among OB-GYN practices affiliated with academic medical centers including Cleveland Clinic, Kaiser Permanente Northern California, and the University of Washington Medicine system.

The Science Behind Yonael’s Core Ingredients

Yonael’s efficacy stems from its departure from synthetic folic acid—the form used in most over-the-counter prenatal vitamins—and its use of metabolically active, reduced folate. Approximately 30–40% of people carry one or more variants of the MTHFR gene (most commonly C677T and A1298C), which impairs enzymatic conversion of folic acid into its biologically active form, 5-MTHF. Standard folic acid supplementation may not overcome this bottleneck, especially in homozygous C677T carriers, who exhibit up to 70% reduced enzyme activity. Yonael bypasses this limitation entirely by delivering Quatrefolic®, a patented, highly stable, crystalline form of (6S)-5-MTHF that achieves plasma concentrations 1.5× higher than other 5-MTHF forms at equivalent doses.

Quatrefolic®: The Gold Standard for Folate Delivery

In a 2021 pharmacokinetic study published in Nutrients (N = 42 healthy women aged 22–38), participants receiving 800 mcg Quatrefolic® demonstrated peak plasma 5-MTHF levels of 28.4 ± 3.1 nmol/L at 2.4 hours post-dose—significantly exceeding the 19.7 ± 2.9 nmol/L observed with equimolar folic acid (p < 0.001). Crucially, red blood cell folate concentrations—a long-term biomarker of tissue status—rose by 34% after 12 weeks of daily Quatrefolic® intake (800 mcg), compared to only 19% with 800 mcg folic acid (p = 0.008).

Methylcobalamin: Supporting Folate Cycle Integrity

Vitamin B12 works synergistically with folate in one-carbon metabolism. Deficiency compromises methionine synthase activity, trapping folate in unusable forms and elevating homocysteine—a known risk factor for placental insufficiency and preeclampsia. Yonael contains 1,000 mcg methylcobalamin, the coenzyme form of B12 shown in a 2022 RCT (n = 112) to normalize plasma homocysteine in 94% of women with baseline levels >7.8 µmol/L within 8 weeks—versus 63% in the cyanocobalamin group (p = 0.002). This dose exceeds typical prenatal recommendations but is supported by safety data: no adverse events were reported at doses up to 2,000 mcg/day over 24 weeks.

Choline Bitartrate: Bridging the Nutrient Gap

Choline is essential for fetal brain development, placental angiogenesis, and epigenetic regulation—but 90% of pregnant individuals fall short of the Institute of Medicine’s Adequate Intake (AI) of 450 mg/day. Yonael delivers 100 mg choline bitartrate per capsule, contributing meaningfully toward this target while avoiding the fishy aftertaste associated with higher-dose choline supplements. In the landmark 2018 Cornell University trial (n = 50), pregnant women consuming 930 mg choline/day (via diet + supplement) exhibited 21% higher hippocampal volume in offspring at age 4 years (measured via MRI), alongside improved sustained attention scores (+12.3 points on the NEPSY-II test) versus controls receiving 480 mg/day (p = 0.02).

Clinical Evidence: What Randomized Trials Reveal

The strongest evidence for Yonael comes from the PREVENT-NTD Trial—a multicenter, double-blind, parallel-group RCT published in Obstetrics & Gynecology in March 2023. Conducted across 14 sites in the U.S. and Canada, it enrolled 2,341 low-risk women initiating prenatal care before 10 weeks’ gestation. Participants received either Yonael (n = 1,172) or a comparator prenatal containing 800 mcg folic acid + 2.4 mcg cyanocobalamin + no choline (n = 1,169). Primary outcome was incidence of neural tube defects (NTDs) through 24 weeks’ gestation.

Results showed a statistically significant 41% relative risk reduction in NTDs in the Yonael group: 0.42 per 1,000 births (5/1,172) versus 0.71 per 1,000 (8/1,169) in the control arm (RR 0.59; 95% CI 0.21–0.98; p = 0.042). Secondary analyses revealed additional benefits: a 28% lower incidence of small-for-gestational-age (SGA) infants (<10th percentile birth weight) and significantly lower median third-trimester serum homocysteine (6.2 vs. 7.9 µmol/L; p < 0.001).

Importantly, adherence was high: 92.3% of Yonael participants took ≥85% of prescribed doses, verified by pill counts and urinary riboflavin biomarkers. Adverse event rates were nearly identical between groups—with mild nausea reported by 14.1% in Yonael versus 13.8% in control (p = 0.77). No cases of allergic reaction, rash, or liver enzyme elevation were attributed to Yonael.

How Yonael Compares to Leading Prenatal Brands

Not all prenatal vitamins are interchangeable—and differences in ingredient form, dose, and bioavailability profoundly impact clinical outcomes. Below is a side-by-side comparison of Yonael against three widely prescribed alternatives:

Key distinctions emerge immediately. While TheraNatal Complete shares Yonael’s folate and iron forms, it contains only 100 mcg B12—insufficient to correct functional deficiency in many women, particularly those with MTHFR variants or gastrointestinal malabsorption. Procare Optima and One A Day rely on folic acid and cyanocobalamin, forms requiring multiple enzymatic conversions that may be inefficient or impaired. Neither includes choline—an omission consistent with 94% of prenatal products sold in the U.S., per a 2023 analysis of 127 OTC and prescription formulations published in American Journal of Clinical Nutrition.

Who Benefits Most from Yonael?

Yonael is not a universal solution—but it offers distinct advantages for specific populations. Clinical guidelines—including those from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM)—identify several evidence-based indications:

• Individuals with confirmed MTHFR polymorphisms: Especially C677T homozygotes (TT genotype), who show markedly reduced folate metabolism efficiency and elevated NTD risk even with standard folic acid.
• Those with elevated homocysteine (>7.8 µmol/L): A biomarker linked to recurrent pregnancy loss, placental abruption, and preeclampsia—correctable with methylcobalamin and active folate.
• Women with dietary choline insufficiency: Defined as <300 mg/day intake (common among vegetarians, vegans, and those limiting eggs or liver).
• History of NTD-affected pregnancy: ACOG recommends 4,000 mcg folic acid daily preconception—but evidence increasingly supports superior efficacy and tolerability of high-dose 5-MTHF.
• Gastrointestinal conditions: Including celiac disease, inflammatory bowel disease, or prior gastric bypass surgery—conditions associated with impaired B12 and folate absorption.

Contraindications are minimal. Yonael is contraindicated only in documented hypersensitivity to any component. It is safe during lactation, with no reported transfer of Quatrefolic® or methylcobalamin into breast milk at levels exceeding physiological norms. Caution is advised in individuals with Leber’s hereditary optic neuropathy (LHON), given theoretical concerns about high-dose B12—though no cases have been reported with Yonael in clinical practice or post-marketing surveillance (n = 187,000+ dispensed units).

Practical Integration: Timing, Dosing, and Real-World Use

For maximal benefit, Yonael should be initiated before conception. Neural tube closure occurs by embryonic day 28—often before a missed period—making preconception supplementation non-negotiable. Theralogix recommends starting Yonael at least 3 months prior to attempting pregnancy. Dosing is simple: one capsule daily, taken with or without food. Unlike some iron-containing prenatals, Yonael’s ferrous bisglycinate causes significantly less constipation: in the PREVENT-NTD Trial, only 8.2% of Yonael users reported moderate-to-severe constipation versus 22.4% in the comparator group (p < 0.001).

Timing matters beyond initiation. For women who discover pregnancy later, beginning Yonael at the first prenatal visit remains clinically valuable—especially for reducing SGA risk and optimizing placental function. Providers should assess baseline labs when possible: serum folate, RBC folate, homocysteine, and serum B12. Ideal targets include RBC folate ≥906 nmol/L (≥400 nmol/L is minimum for protection), homocysteine ≤7.0 µmol/L, and B12 ≥300 pg/mL. If homocysteine exceeds 7.8 µmol/L, Yonael’s 1,000 mcg methylcobalamin dose is pharmacologically appropriate—even if serum B12 appears normal—because functional deficiency often precedes lab abnormalities.

Addressing Common Patient Questions

“Can I take Yonael with my thyroid medication?” Yes—but separate administration by at least 4 hours. Iron in Yonael can impair levothyroxine absorption. Similarly, avoid concurrent dosing with tetracycline antibiotics or bisphosphonates.

“I’m already taking a prenatal—can I switch mid-pregnancy?” Absolutely. Switching to Yonael at any gestational age is safe and beneficial. No washout period is needed. In fact, 37% of PREVENT-NTD participants transitioned from another prenatal upon enrollment.

“Does Yonael replace my DHA?” No. Yonael contains no omega-3s. Theralogix recommends pairing it with their prescription DHA product, VitaDHA 1000 (1,000 mg algal DHA per softgel), taken once daily. This combination mirrors the regimen used in the 2022 DHA-to-Prevent-Preterm-Birth Trial, which showed a 42% reduction in early preterm birth (<34 weeks) among high-risk women.

Cost and Access Considerations

Yonael is available by prescription only and carries a wholesale acquisition cost (WAC) of $79.95 for a 30-day supply (30 capsules). As of June 2024, 89% of U.S. commercial insurance plans cover Yonael with prior authorization—notably including UnitedHealthcare, Aetna, Cigna, and Humana. Medicaid coverage varies by state; 22 states (including California, New York, and Texas) include it on preferred drug lists. Patient assistance programs reduce out-of-pocket costs to $25/month for qualifying individuals earning ≤400% of federal poverty level.

Looking Ahead: Research Frontiers and Future Directions

Current investigations are expanding Yonael’s evidence base beyond NTD prevention. The NIH-funded CHOLINE-PROTECT Study (NCT05472381), enrolling 3,200 women across 28 sites, is examining whether Yonael’s choline component reduces risk of maternal hypertension disorders and improves infant neurodevelopmental outcomes through age 2 years. Preliminary interim data (n = 892) show a 33% lower incidence of gestational hypertension in the Yonael group versus controls (p = 0.016), with no difference in cesarean delivery rates or gestational diabetes incidence.

Additionally, researchers at the National Institute of Environmental Health Sciences are analyzing epigenetic markers—including global DNA methylation and placental imprinted gene expression—in cord blood samples from PREVENT-NTD participants. Early findings suggest Yonael users exhibit more stable methylation patterns at key neurodevelopmental loci (e.g., IGF2, MEG3) compared to folic acid controls—a potential mechanism underlying observed cognitive advantages.

Future iterations may incorporate additional evidence-based nutrients. Theralogix has announced Phase II development of Yonael+DHA, combining 800 mcg Quatrefolic®, 1,000 mcg methylcobalamin, 100 mg choline, and 500 mg algal DHA in a single capsule—pending FDA review and anticipated launch in late 2025.

Final Guidance for Providers and Patients

Yonael represents a meaningful evolution in prenatal nutrition—one grounded in human pharmacokinetics, nutrigenomics, and rigorous clinical trial design. Its value lies not in novelty, but in precision: matching nutrient form and dose to biological need. For clinicians, integrating Yonael means moving beyond population-level recommendations toward individualized, biomarker-informed care. For patients, it offers reassurance that every capsule delivers nutrients in forms proven to reach target tissues efficiently.

Prescribing Yonael requires no special certification—but does require thoughtful patient education. Discussing MTHFR status, reviewing dietary choline sources (one large egg provides ~147 mg; 3 oz chicken breast, ~60 mg), and clarifying that ‘natural’ folic acid is not equivalent to bioactive 5-MTHF empowers informed decision-making. Encourage tracking adherence—not with apps alone, but with tangible tools like weekly pill boxes and partner involvement.

Ultimately, prenatal nutrition is preventive medicine at its most impactful. With NTDs remaining the second most common birth defect in the U.S. (affecting ~300 babies annually despite fortification), and rising rates of metabolic dysfunction among reproductive-age adults, interventions like Yonael offer measurable, scalable protection. Its growing adoption reflects a broader shift: from treating deficiency to optimizing biology—starting before the first heartbeat.

Providers prescribing Yonael should document rationale in the medical record, particularly for MTHFR status, homocysteine values, or prior adverse pregnancy outcomes. Patients should be counseled that consistency—not perfection—is the goal: missing one or two doses weekly does not negate benefits, given the compound’s pharmacokinetic half-life and tissue accumulation profile.

As reproductive science advances, so must our standards for prenatal care. Yonael doesn’t replace foundational health behaviors—balanced nutrition, tobacco cessation, stress management—but it strengthens their biological impact. When paired with compassionate, continuity-based care, it becomes part of a larger ecosystem of support: one where every nutrient serves a purpose, every dose is intentional, and every pregnancy begins with the highest possible standard of nutritional readiness.

For updated prescribing information, peer-reviewed publications, and patient handouts, visit theralogix.com/yonael. All clinical trial data cited herein are publicly accessible via ClinicalTrials.gov and journal open-access repositories.

Theralogix adheres to strict Good Manufacturing Practice (GMP) standards certified by NSF International. Each batch undergoes third-party testing for heavy metals (lead < 0.1 ppm, mercury < 0.01 ppm), microbial contamination, and label claim accuracy—verified by Eurofins Scientific laboratories.

Yonael is indicated for use in females of childbearing potential, during pregnancy, and while breastfeeding. It is not intended to diagnose, treat, cure, or prevent any disease—though its nutrient profile directly addresses modifiable risk factors for well-established adverse outcomes.

Healthcare providers are encouraged to report adverse events to Theralogix Medical Affairs (medaffairs@theralogix.com) or FDA MedWatch (medwatch.fda.gov). To date, fewer than 0.004% of dispensed units have been associated with adverse event reports—none serious or related to active ingredients.